Lianhua Qingwen(Forsythiae fructus 225 mg, Lonicerae japonicae flos 225 mg, Ephedrae herba (processed w/ honey) 85 mg, Armeniacae semen amarum (stir-baked) . Therefore, further attention should be paid to the occurrence of adverse reaction with LHQW among different age groups in the future. LHQW had been proven to accelerate the improvement of acute exacerbation of COPD (AECOPD) patients, especially for the high-risk subgroup, due to the decreased release of inflammatory mediators including IL-8, TNF- , IL-17, and IL-23 [38]. Wang, Y., Greenhalgh, T., and Wardle, J. Chin. Efficacy and safety of Lianhua Qingwen combined with - PubMed Till August 8, 2020, over 19,000,000 people have been confirmed infected and more than 700,000 people have died during this severe viral prevalence. Res. Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats Niu Q.Q., Chen Y., Liu Y., Mao S.Z., Wang H., Zheng W.K., Zhang J.H. The post-marketing monitoring data incorporated information on the following gastrointestinal adverse reactions: nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth; as well as skin rash, itching, dizziness (Yiling Pharmaceutical, 2021). There was no statistically significant difference in the incidence of psychiatric disorders between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.253.97, p = 1.000). The current. Results were reported as risk ratio (RR) with 95% confidence interval (CI). Shi, M., Peng, B., Li, A., Li, Z., Song, P., Li, J., et al. J. Intern. Preliminary Study on the Inhibitory Effect of Lianhua Qingwen Capsule on virusMaster Degree. [13], A 2020 "randomized controlled trial" of LHQW involving Zhong was also found in April 2022 to have undisclosed funding from Yiling Pharmaceuticals, forcing an erratum. Expert: Lianhua Qingwen capsule proven effective for COVID-19 - CGTN Drug-Use Hospitals China. Data analysis were done by CH and DZ. Jia W., Wang C., Wang Y., Pan G., Jiang M., Li Z., Zhu Y. Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS. Wang C.H., Zhong Y., Zhang Y., Liu J.P., Wang Y.F., Jia W.N., Wang G.C., Li Z., Zhu Y., Gao X.M. [Saururaceae; Houttuyniae Botanical drug] (255g), Pogostemon cablin (Blanco) Benth. Now, there are no study results posted on ClinicalTrials.gov for this study yet. (1990). Figure 1 provides a detailed flowchart of the screening process. Jie Chen, Qin Chen and Hua-Qian Jin analyzed literatures. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. No statistical difference was detected for sleepy. (2015). In a lipopolysaccharide (LPS)-induced acute lung injury animal model, LHQW could efficiently decrease the chemotaxis of monocytes toward the pulmonary infection foci, and thus blocked the disease development by down-regulating MCP-1 expression [33]. LHQW was initially approved by the China Food and Drug Administration (CFDA) in 2004 and represents the first traditional Chinese medicine that passed the rapid drug approval channel of CFDA for treatment of severe acute respiratory syndrome (SARS). 81503129, No. LHQW, an innovative proprietary traditional Chinese medicine used to treat influenza, was approved by the Food and Drug Administration of the United States for Phase II of clinical trial in 2015 (Ye et al., 2020). In another prospective multicenter randomized controlled trial in confirmed COVID-19 cases, Hu et al. (japanese honeysuckle) flower 27.41 mg, gypsu . As COVID-19 has led to serious death and lacks treatment strategies, the potential therapeutic drugs are increasingly being explored. Peng L.L., Li L., Shen L., Li X.L. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. LHQW: Lianhua Qingwen. [4][7], Lianhua Qingwen should be avoided for patients with G6PD deficiency, since its active ingredient, Lonicera japonica, will lead to hemolysis to such patients. National Administration of Traditional Chinese Medicine: Traditional Chinese Medicine Is Involved in a Wide Range of Treatment and Early Intervention Has Good Effects. The site is secure. This work was supported by the National Natural Science Foundation of China (No. Yang C.X., Qu J., Liu Y.T., Meng S.W., Wang B.L., Feng M.Q., Sun Y. Besides, on April 14, 2020, the National Medical Products Administration of China approved modifying the specification of LHQW (Yiling Pharmaceutical Inc.) by adding a new indication for COVID-19 treatment in mild and normal cases. aDepartment of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, PR China, bShanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, PR China, cShanghai TCM-Integrated Institute of Vascular Anomalies, Shanghai, 200082, PR China, dDepartment of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, 310018, PR China, eDepartment of Pharmacy, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310018, PR China, fState Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Science, Nanjing University, Nanjing, 210023, PR China. Twenty-six studies focused on treatment of common pneumonia, of which 23 reported adverse reactions. A Working List of All Plant Species. Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . SuperHealthGuard and Loyal Great International Ltd. - 608633 - 06/26 No meta-regression was performed for COVID-19 pneumonia due to the limited number of studies. Traditional Chinese medicine has accumulated substantial clinical experience over thousands of years. Evid. Res. Recent study then showed that the main components of LHQW included chlorogenic acid, caffeic acid, isochlorogenic acid B, isochlorogenic acid C, phillyrin, forsythiaside A, and rutin by high performance liquid chromatography (HPLC) analysis [19]. Subgroup analysis showed a lower level of nausea or vomiting in LHQW group (RR = 0.60, 95% CI = 0.480.74, p < 0.001), no statistical difference was detected for other symptoms of gastrointestinal system damage. 7 (3), 177188. LQ15H280003), the Clinical Research Projects of Zhejiang Medical Association (No. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D. A novel coronavirus from patients with pneumonia in China, 2019. Med. (2010). COVID-19 pandemic has caused a serious threat to public health and become the greatest challenge facing the world. Accordingly, other biases were defined as low risk of bias. The risk of bias data is presented as a percentage, as shown in Figure 2. Rev. The results are expected to enhance its effectiveness against viruses. The majority of studies lacked sufficient description of allocation concealment and therefore, the project was predominantly evaluated as unclear risk of bias. Although the blinding method was not reported, since some symptom indicators needed measurement with instruments, assessment of symptom indicators was unlikely to be affected by the lack of blinding. First, the quality of qualified studies was generally medium, randomization procedures and blinding information were lacking in most studies. The current meta-analysis was conducted to systematically evaluate the security of LHQW compared with conventional drug in clinical application. aimed to assess the efficacy and safety of LH combined with usual treatment vs usual treatment alone in treating mild or moderate COVID-19 by a meta-analysis of randomized controlled trials (RCTs). Due to the low quality of the clinical research, the accuracy of this conclusion needs to be conducted to verify. An article on telemedicine and medical news platform Dr. Lilac pointed out that there was no scientific evidence available to indicate that LHQW was effective as prophylaxis to prevent infection, nor did there exist any official government recommendation for such usage; instead, taking the drug unnecessarily carried a risk of side effects. Plants of the World Online. To clarify the in vivo effects of LHQW, Gao and colleagues recently showed that LHQW could treat influenza A virus infection in H1N1 mouse model by improving pathologic alterations and body weight loss, and reducing virus replication, lung lesions as well as inflammation [19]. The Cochrane Collaboration risk of bias tool comprising seven items was applied to assess the risk of bias of each eligible study (Higgins et al., 2011). Few reports of adverse reactions in the course of treating COVID-19 pneumonia with LHQW are available. In mice after infected with the flu virus FM1, LHQW capsule obviously increased IFN- content in lung homogenate and significantly reduced the levels of TNF-, IL-1 and IL-6 in lung tissues, and had inhibiting effect on the marked decrease of CD4+ and CD4+/CD8+ [31,32]. (10), 100. FOIA (2016). Drugs and Clinic. Med. Data were considered statistically significant at p values <0.05. Zhu S.Y., Li X.Y., Wei Y.L., Yang P.Y., Qin E.D. [2] In the practice of TCM, LHQW is considered to have the effects of clearing excessive heat, removing toxins, improving lung ventilation, and discharging heat. Are there any known contraindications? However, since subgroup and sensitivity analyses did not explore the source of heterogeneity, we utilized meta-regression to determine the potential underlying factors. Careers, Unable to load your collection due to an error. Ren Y., Yao M.C., Huo X.Q., Gu Y., Zhu W.X., Qiao Y.J., Zhang Y.L. The serious attack of Coronavirus Disease 2019 (COVID-19), infected by Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (SARS-CoV-2), has quickly spread around the globe [[1], [2], [3]]. 6 (26), 8485. The group reported significantly lower incidence of adverse reactions (RR = 0.62, 95% CI = 0.460.82) and lower incidence of gastrointestinal system damage in the LHQW group (RR = 0.65, 95% CI = 0.460.92) relative to the control group. Copyright 2022 Hu, He, Gong, Liang, Zhao and Zhang. This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. [18], In Singapore, the Health Sciences Authority has issued an advisory to clarify that although it has been approved for sale as a Chinese proprietary medicine for the relief of cold and flu symptoms, Lianhua Qingwen is not approved to treat or alleviate symptoms of COVID-19. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. However, no consensus has been reached on the security of LHQW to date. LHQW has been recommended by the China International Exchange and Promotive Association for Medical and Health Care and the Chinese Research Hospital Association as comprehensive treatment for moderate or chronic COVID-19 pneumonia in conjunction with routine therapy (Jin et al., 2020). The sensitivity results are shown in Table 2. 8600 Rockville Pike "This medicine has a cooling effect so if you take this, lalo kang magchi -chill," he cautions. 56 (2), 455463. Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. government site. It blocked the early stages (02h) of virus infection, and reduced virus-induced nuclear factor-kappa B (NF-B) activation and the gene expression of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-, interferon-inducible protein (IP)-10, and monocyte chemoattractant protein (MCP)-1 [24]. Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology. Pharmacokinetics-based identification of pseudoaldosterogenic compounds doi:10.11954/ytctyy.201608076, Chan, K. W., Wong, V. T., and Tang, S. C. W. (2020). For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). These in vivo data further demonstrate the antiviral effects of LHQW as well as its lung protection role. [Lamiaceae; Pogostemonis Botanical drug] (85g), Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (51g), Rhodiola crenulata (Hook. Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee301c485bc799cf (Accessed July 23, 2021). Compared with the conventional drug group, the incidence of disease recurrence was lower in the LHQW group, implied that LHQW might could regulate and enhance the immune function of the body. Lianhua Qingwen Capsule for pneumonia treatment Cheng D.Z., Wang W.J., Li Y., Wu X.D., Zhou B., Song Q.Y. Analysis of Clinical Application and Adverse Reactions of Houttuynia Cordata Injection. There was no statistically significant difference in the incidence of adverse reactions during treatment of respiratory tract infection between the LHQW group and the conventional drug group (RR = 0.78, 95% CI = 0.581.03, p = 0.083). There was no statistically significant difference in the incidence of adverse reactions during treatment of viral influenza between the LHQW group and the conventional drug group (RR = 0.75, 95% CI = 0.471.21, p = 0.244). 367 (6485), 14121413. Liu Y., Liu L., Cao M.M., Wen J., Zhou S., Jiang H., Zhang Y., Zhao R.S., Yang Y.H. Efficacy and Safety of Lianhua Qingwen Granule Combined with Oseltamivir in the Treatment of Influenza Virus Infection in Children. the Need for Accurate Scientific Nomenclature for Plants. Conclusion: The current study provides potential a reference for the security of LHQW. the contents by NLM or the National Institutes of Health. Beggs test and Eggers test detected no visible publication bias for data from pooled studies and disease evaluation. It warned that sellers who make claims that it can prevent, protect against or treat COVID-19 may face prosecution. vahl (weeping forsythia) fruit 27.41 mg, Lonicera japonica Thunb. [Systematic review of efficacy and safety of Lianhua Qingwen - PubMed Nevertheless, none of the in vivo studies are directly focused on Corona virus or COVID-19. CFDA has recently approved adding a new indication for LHQW in mild and common COVID-19 patients, but whether it would bring benefits for the severe cases is unclear. In the evaluation of security indexes, LHQW group has a reduced incidence of respiratory system damage, skin and its appendages injury, nervous system damage and gastrointestinal system damage, along with other adverse reactions. Subgroup analysis showed the incidence of dizziness or headache was significantly reduced with LHQW group (RR = 0.54, 95% CI = 0.340.84, p = 0.006), no statistical difference was detected for drowsiness and legacy neuralgia. 13 (08), 676681. Other Symptoms Sputum.Four studies reported the effects of Lianhua Qingwen and those of conventional drugs on the duration of sputum. World Health Organization Adverse Drug Reaction Terminology (2009). Twenty-three studies on other diseases were included, with 12 reporting adverse reactions. Flow chart of the search and selection process. Ther. doi:10.1111/jep.13614, Wang, Y. X., Zhang, K. Y., Huang, J. H., Han, S. L., Zhao, J. H., and Xu, Z. J. 52 (3), 5860. However, no consensus has been reached on the security of LHQW to date. Effect of Lianhua Qingwen capsule on immunity of mice infected with flu virus. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Pharmacol. Wang et al. TABLE 2. Li H.R., Chang L.P., Wei C., Jia Z.H. ADVERSE REACTION Uncertainty. Further evaluation revealed that LHQW significantly inhibited SARS-CoV-2 replication in Vero E6 cells, markedly reduced pro-inflammatory cytokines (TNF-, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production and resulted in abnormal particle morphology of virion in cells [30].